TrialCardiovascular diabetology2021

Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial.

Atsushi Tanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.